Eli Lilly & Co. reported fourth- quarter earnings that beat analyst estimates as sales of its top-selling drug, the Cymbalta depression treatment, increased 20 percent, helped by higher prices in the U.S. Earnings excluding one-time items of 85 cents a share were more than the 79-cent average of 17 analyst estimates compiled by Bloomberg.
URL: http://www.topix.com/health/depression/2013/01/lilly-profit-beats-analyst-estimates-as-cymbalta-sales-climb?fromrss=1
No comments:
Post a Comment